Anti-GSK-3α/β Monoclonal Antibody for WB, IF/ICC, IF-P, IHC-P, ELISA - P49840/P49841

Core Product Specifications and Parameters

Biological Background: GSK-3α/β Function and Localization

• GSK-3α and GSK-3β are constitutively active serine/threonine kinases that phosphorylate and inactivate glycogen synthase (GYS1/GYS2), thereby negatively regulating glycogen synthesis and glucose homeostasis.
  Related references: PMID:11749387, PMID:17478001, PMID:19366350
• They play a pivotal role in the Wnt/β-catenin signaling pathway by phosphorylating β-catenin (CTNNB1), promoting its ubiquitination and proteasomal degradation, which inhibits Wnt target gene transcription.
  Related references: PMID:17229088
• GSK-3α contributes to Alzheimer disease pathogenesis by facilitating amyloid precursor protein (APP) processing and the generation of neurotoxic amyloid plaques.
  Related references: PMID:12761548
• The kinases are involved in insulin signaling: they may mediate the development of insulin resistance by regulating transcription factors that control metabolic genes.
  Related references: PMID:10868943, PMID:17478001
• GSK-3α regulates autophagy by phosphorylating the acetyltransferase KAT5/TIP60 under starvation conditions, which in turn acetylates and activates key autophagy proteins like ULK1 and RUBCNL.
  Related references: PMID:30704899
• Both isoforms feature an N-terminal kinase domain with ATP-binding and nucleotide-binding sites, and their activity is modulated by upstream kinases through phosphorylation at specific N‑terminal serine residues (Ser21 for GSK-3α, Ser9 for GSK-3β). Dysregulation is linked to diabetes, neurodegeneration, and cancer.

Experimental Guidance and Technical Tips

• For Western blotting, expect bands at approximately 46 kDa (GSK-3α) and 48 kDa (GSK-3β) in cell or tissue lysates from human, mouse, or rat. Use standard SDS-PAGE and nitrocellulose/PVDF membranes.
• In immunofluorescence (IF/ICC) and immunohistochemistry (IHC), permeabilize cells or deparaffinize and antigen-retrieve tissues appropriately, as GSK-3α/β are predominantly cytoplasmic but may also localize to nuclei. Validate signal specificity with known positive and negative controls.
• For ELISA, consider a sandwich format using this capture antibody paired with a detection antibody that recognizes a different epitope. Titrate antibody concentrations to optimize signal-to-noise ratio.
• The recombinant protein immunogen suggests the antibody may recognize both phosphorylated and unphosphorylated forms. Verify recognition of the desired modification state by treating samples with modulators (e.g., insulin or Wnt3a to induce phosphorylation, or phosphatase inhibitors to preserve endogenous states).
• Cross-reactivity with mouse and rat orthologs is reported; however, always confirm reactivity in your specific model system, as expression levels and post-translational modifications may vary.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a one-stop sourcing partner for diagnostic developers and research laboratories, offering validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents. With a focus on metabolism and signal transduction targets like GSK-3α/β, we streamline procurement of high-quality IVD raw materials to accelerate your assay development from concept to clinic.